Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome

PloS One
Sheng-Mou HsiaoHann-Chorng Kuo

Abstract

To analyze the predictors of therapeutic efficacy after intravesical botulinum toxin A injection for overactive bladder syndrome (OAB) refractory to antimuscarinic therapy. All consecutively OAB patients, who visited the urologic outpatient clinics of a medical center and refractory to antimuscarinic treatment, were prospectively enrolled. All enrolled patients received intravesical injection of 100 U onabotulinumtoxinA (Botox). The Global Response Assessment (GRA) score ≥ 2 at 3 months after Botox injection was defined as a successful treatment, otherwise failed. Overall, 89 patients received intravesical injection. Eighty patients, including 42 men and 38 women, had received follow-up at 3 months. The overall success rate was 63.8%. The global response assessment, urgency severity score, urgency, urgency urinary incontinence and frequency episodes, and functional bladder capacity improved after treatment. However, post-void residual volume (PVR) increased, and voiding efficiency (VE) decreased after treatment. Female gender (odds ratio = 3.75) was the only independent factor associated with the success. Female gender (coefficient = 0.74), low baseline overactive bladder symptoms score (coefficient = -0.12) and the presence of...Continue Reading

References

Jun 12, 1987·JAMA : the Journal of the American Medical Association·N M Resnick, S V Yalla
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
May 20, 2005·American Journal of Obstetrics and Gynecology·Matthias WernerBernhard Schüssler
May 24, 2008·The Journal of Urology·Linda BrubakerUNKNOWN Pelvic Floor Disorders Network
Jul 24, 2012·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Hann-Chorng Kuo
Mar 16, 2013·Neurourology and Urodynamics·Sheng-Mou HsiaoHann-Chorng Kuo

❮ Previous
Next ❯

Citations

Dec 11, 2019·Neurourology and Urodynamics·Christopher ChermanskyArun Sahai
Feb 15, 2020·Investigative and Clinical Urology·Jing-Liang Chen, Hann-Chorng Kuo
Jul 22, 2020·Der Urologe. Ausg. A·B K ZiegelmüllerR M Bauer

❮ Previous
Next ❯

Software Mentioned

STATA

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.